
Opinion|Videos|April 30, 2024
Enhancing Hepatic Encephalopathy Care through Pharmacist-Prescriber Collaboration
KOLs emphasize the crucial role of collaboration between pharmacists and physicians in managing hepatic encephalopathy, stressing the importance of monitoring sedating medications, polypharmacy, and patient response to HE therapy, while making necessary adjustments to optimize care.
Advertisement
Episodes in this series

Advertisement
Related to this article

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

Pharmacists can help identify uncontrolled risk factors, review medications, and reinforce when patients should seek emergency care.

The anti-CD20 antibody is the first drug approved specifically for the disease, based on phase 3 MAJESTY data showing higher remission vs tacrolimus.

In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.

From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.

Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Structured Blood Glucose Testing: Why Timing Matters
2
Glucose Monitoring: Timing Makes Every Reading Count
3
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
4
Navigating State Vaccine Regulations: Challenges for Community Pharmacies
5



